GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Diabetes Care, American Diabetes Association, ( 2023-09-06)
    Abstract: To assess anxiety and risk perception among parents whose children screened positive for islet autoantibodies, indicating elevated risk for type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS The Autoimmunity Screening for Kids (ASK) study identified 319 children age 1 to 17 years at risk for T1D via screening for islet autoantibodies; 280 children with confirmed islet autoantibodies and their caregivers enrolled in a follow-up education and monitoring program to prevent diabetic ketoacidosis at diagnosis. Parents completed questionnaires at each monitoring visit, including a six-item version of the State Anxiety Inventory (SAI), to assess anxiety about their child developing T1D, and a single question to assess risk perception. RESULTS At the first ASK follow-up monitoring visit, mean parental anxiety was elevated above the clinical cutoff of 40 (SAI 46.1 ± 11.2). At the second follow-up monitoring visit (i.e., visit 2), mean anxiety remained elevated but started to trend down. Approximately half (48.9%) of parents reported their child was at increased risk for T1D at the initial follow-up monitoring visit (visit 1). Parents of children with more than 1 islet autoantibody (IA) and a first-degree relative with T1D were more likely to report their child was at increased risk. CONCLUSIONS Most parents of autoantibody-positive children have high anxiety about their child developing T1D. Information about the risk of developing T1D is difficult to convey, as evidenced by the wide range of risk perception reported in this sample.
    Type of Medium: Online Resource
    ISSN: 0149-5992 , 1935-5548
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2023
    detail.hit.zdb_id: 1490520-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2023
    In:  SLEEP Vol. 46, No. Supplement_1 ( 2023-05-29), p. A336-A336
    In: SLEEP, Oxford University Press (OUP), Vol. 46, No. Supplement_1 ( 2023-05-29), p. A336-A336
    Abstract: Sleep is recognized as an important component of health for people with type 1 diabetes (T1D), with significant associations identified between sleep quality, glycemic outcomes, and diabetes self-management. Adolescents, who are particularly vulnerable to insufficient sleep and have difficulty meeting glycemic targets, typically experience differences in sleep during the summer versus school months. We examined barriers to sufficient sleep during summer and fall months amongst adolescents ages 11-17 with T1D. Methods Adolescents (n=10, mean age 14.1 years, 40% female, 80% non-Hispanic White) with T1D participated in qualitative, semi-structured interviews to explore seasonal differences in barriers to sleep. Interviews were audio and video recorded, transcribed using Otter-AI software with manual review for accuracy, independently coded by two trained research staff, and themes were identified. Results Interviews were completed by five adolescents during the summer and five during school months. Barriers to achieving sufficient sleep for both time periods included diabetes-related issues (e.g. hypoglycemic episodes, glucose variability, fear of hypoglycemia, and device use), peers, activities, and family factors. School, activities, family and diabetes disruptions were equally prominent barriers during the school year, whereas diabetes disruptions were the most common barriers during the summer. While device alarms disrupted sleep at both times, adolescents reported that diabetes technologies had an overall net positive impact on sleep during the school year due to reduced worry, but a neutral impact during the summer. Adolescents agreed it would be helpful to talk about sleep concerns or ways to improve sleep. Conclusion Diabetes management is a consistent reason for insufficient sleep duration in adolescents with T1D. In addition, similar to adolescents without T1D, academic, social, and family obligations were barriers to obtaining sufficient sleep during the school year. While some sleep disruptors may not be modifiable, assessment by a clinician who can provide guidance on methods to improve sleep health may be beneficial and well received. Because diabetes health care providers have frequent contact, routine visits provide an opportunity to identify sleep concerns and provide both diabetes and non-diabetes guidance to address sleep health. Further exploration of sleep behaviors and barriers in adolescents with T1D is warranted. Support (if any) 5-ECR-2022-1179-A-N, JDRF and Helmsley
    Type of Medium: Online Resource
    ISSN: 0161-8105 , 1550-9109
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 2056761-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Preventing Chronic Disease, Centers for Disease Control and Prevention (CDC), Vol. 15 ( 2018-04-26)
    Type of Medium: Online Resource
    ISSN: 1545-1151
    Language: English
    Publisher: Centers for Disease Control and Prevention (CDC)
    Publication Date: 2018
    detail.hit.zdb_id: 2135684-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society, ( 2021-08-03)
    Abstract: Single ZnT8 autoantibody (ZnT8A) positivity by standard radiobinding assay (RBA) is commonly seen in nondiabetes population-based screening and the risk of progression to type 1 diabetes (T1D) in subjects with single ZnT8A is unknown. Objective Identify the risk of progression to T1D in individuals positive only for ZnT8A. Methods We developed an electrochemiluminescence (ECL) assay to detect high-affinity ZnT8A and validated it in 3 populations: 302 patients newly diagnosed with T1D, 135 nondiabetic children positive for ZnT8A by RBA among 23 400 children screened by the Autoimmunity Screening for Kids (ASK) study, and 123 nondiabetic children multiple autoantibody positive or single ZnT8A positive by RBA participating in the Diabetes Autoimmunity Study in the Young (DAISY). Results In 302 patients with T1D at diagnosis, the positivity for ZnT8A was 62% both in RBA and ECL. Among ASK 135 participants positive for RBA-ZnT8A, 64 were detected ZnT8A as the only islet autoantibody. Of these 64, only 9 were confirmed by ECL-ZnT8A, found to be of high affinity with increased T1D risk. The overall positive predictive value of ECL-ZnT8A for T1D risk was 87.1%, significantly higher than that of RBA-ZnT8A (53.5%, P  & lt; .001). In DAISY, 11 of 2547 children who had no positivity previously detected for other islet autoantibodies were identified as single ZnT8A by RBA; of these, 3 were confirmed positive by ECL-ZnT8A and all 3 progressed to clinical T1D. Conclusion A large proportion of ZnT8A by RBA are single ZnT8A with low T1D risk, whereas ZnT8A by ECL was of high affinity and high prediction for T1D development.
    Type of Medium: Online Resource
    ISSN: 0021-972X , 1945-7197
    RVK:
    Language: English
    Publisher: The Endocrine Society
    Publication Date: 2021
    detail.hit.zdb_id: 2026217-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Diabetes, American Diabetes Association, Vol. 71, No. Supplement_1 ( 2022-06-01)
    Abstract: Introduction: Poorer outcomes in acute and late complications of type 1 diabetes (T1D) persist among racial/ethnic minorities, and technology adoption may be lower in these groups. Technologies such as continuous glucose monitors (CGM) and insulin pumps (CSII) enhance diabetes management and improve glycemic control. We examined differences in use of diabetes technology by race/ethnicity among patients 12 and older followed at the Barbara Davis Center who had T1D for at least 1 year. Methods: Use of CGM and/or CSII vs. neither was examined in 5,539 patients by racial/ethnic groups: Non-Hispanic White (NHW, n=3,945) , Black (n=161) , Hispanic (n=719) and Other racial groups (OR, n=714) . General liner models compared HbA1c and technology use by race/ethnicity. Results: Black, Hispanic and OR patients were younger, had shorter T1D duration, higher HbA1c and less use of technology. In linear models adjusted for age, diabetes duration and visits over the past year, use of technology was associated with lower HbA1c in each race/ethnic group. However, among technology users, minority patients had higher HbA1c compared to NHW patients. Conclusion: HbA1c was highest and diabetes technology use lowest among Blacks and Hispanics. Efforts to increase technology use for diabetes management in these populations may result in greater glycemic control and ultimately the reduction of acute and late complications of diabetes. Disclosure B.Conway: None. V.Shah: Advisory Panel; Medscape, Sanofi, Consultant; Dexcom, Inc., Research Support; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk. C.Geno rasmussen: None. A.Gerard gonzalez: n/a. J.K.Snell-bergeon: Stock/Shareholder; GlaxoSmithKline plc. Funding NIH grant P30-DK116073
    Type of Medium: Online Resource
    ISSN: 0012-1797
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2022
    detail.hit.zdb_id: 1501252-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Diabetes, American Diabetes Association, Vol. 70, No. Supplement_1 ( 2021-06-01)
    Abstract: Background: A cohort of children with single ZnT8 autoantibody (ZnT8A) positivity were identified in two large clinical trials, Autoimmunity Screening for Kids (ASK) and Diabetes Autoimmunity Study in the Young (DAISY), and their risk of type 1 diabetes (T1D) have never been studied. Methods: Three cohorts were analyzed using a high-affinity electrochemiluminescence (ECL) ZnT8A assay including 302 new onset T1D patients, 135 children positive for ZnT8A by standard radio-binding assay (RBA) from 23400 children screened in ASK study, and 123 children with multiple autoantibodies or single ZnT8A by RBA from 2547 children in DAISY study. Results: ECL-ZnT8A had a similar sensitivity with RBA-ZnT8A in the cohort of 302 new onset T1D patients (62.3% vs. 61.9%). In ASK, 135/23400 of general population children were positive for RBA-ZnT8A and 64/135 were found as single ZnT8A only without other islet autoantibodies. Of 64 children with single ZnT8A, only 14.1% (9/64) were detectable by ECL-ZnT8A. Antibody-affinity analysis revealed that the ZnT8A in RBA but not confirmed by ECL were of low affinity and they were easily disappeared during the follow-up behaving as ‘transient’ positivity. In terms of T1D classification from stage 1 to stage 3, positive predictive value (PPV) of ECL-ZnT8A (61/70 [87.1%]) was significantly higher than that of RBA-ZnT8A (73/137 [53.3%] ; P & lt;0.0001). The cumulative risk of clinical T1D development with ZnT8A confirmed by ECL (16/66) was significantly enhanced during a short time of follow-up, compared with ZnT8A not confirmed by ECL (1/43; p=0.023). Similarly in DAISY participants, 11/2547 children were identified as single ZnT8A by RBA while only three who developed T1D were detected ECL-ZnT8A. Conclusions: Large proportion of ZnT8A by current standard RBA are single ZnT8A with majority at low risk in population-based screening while ECL-ZnT8A can discriminate high risk from low risk and are highly predictive for T1D development. Disclosure X. Jia: None. L. He: None. D. Miao: None. K. Waugh: None. C. Geno rasmussen: None. F. Dong: None. M. Rewers: Advisory Panel; Self; Provention Bio, Inc., Consultant; Self; RTI, Research Support; Self; Janssen Research & Development, LLC, JDRF. L. Yu: None. Funding Diabetes Research Center (P30DK116073); JDRF (2-SRA-2018-533-S-B, 2-SRA-2020-965-S-B, 1-SRA-2016-208-S-B); National Institutes of Health (DK32083)
    Type of Medium: Online Resource
    ISSN: 0012-1797 , 1939-327X
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2021
    detail.hit.zdb_id: 1501252-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Diabetes Association ; 2021
    In:  Diabetes Vol. 70, No. Supplement_1 ( 2021-06-01)
    In: Diabetes, American Diabetes Association, Vol. 70, No. Supplement_1 ( 2021-06-01)
    Abstract: Background: Type 1 diabetes (T1D), a major chronic autoimmune disease starting mostly from childhood, is now predictable with the measurement of four major islet autoantibodies (IAbs) including IAA, GADA, IA-2A and ZnT8A. Currently, there are approximately 1.4 million people affected with T1D in the United States and the incidence has doubled in the last 20 years, especially in young children. Mass screening for eligible subjects and the general population remains inefficiency and laborious bottleneck. Methods: With the platform of our extensively validated high affinity electrochemiluminescence (ECL) assay, we have developed a simple multiplexed ECL assay to combine all four major IAb assays in a single well. Two cohorts were studied including 80 samples from newly diagnosed patients with T1D and 1,140 from Autoimmunity Screening for Kids (ASK) study. Both multiplex ECL assay and standard radio-binding assay (RBA) were performed in parallel. Results: With & gt;99th percentile of specificity for both assays in over 1,000 samples from general population, sensitivity of multiplex ECL assay in new onset patients with T1D were similar to RBA, GADA 75% vs. 71%; IA-2A 91% vs. 90%; IAA 61% vs. 65%; ZnT8A 90% vs. 87%. In ASK cohort, multiplex ECL assay was concordant with RBA among children with multiple IAbs (42/44, 96%). In contrast, only 39% (21/54, p & lt;0.0001) of children with single IAb by RBA were positive by multiplex ECL assay. Conclusion: Multiplex ECL assay illustrated its high sensitivity/specificity as RBA in T1D patients. In general population screening, multiplex ECL assay, similar to single ECL assay, is capable to discriminate high risk IAbs from low risk IAbs generated by RBA. With a multiplexing feature, it provides a high throughput tool with low cost and low sample volume for large scale of population screening for T1D. Disclosure L. He: None. X. Jia: None. D. Miao: None. C. Geno rasmussen: None. M. Rewers: Advisory Panel; Self; Provention Bio, Inc., Consultant; Self; RTI, Research Support; Self; Janssen Research & Development, LLC, JDRF. L. Yu: None. Funding JDRF (2-SRA-2018-533-S-B, 1-SRA-2016-208-S-B); National Institutes of Health (DK32083); Diabetes Research Center (P30DK116073)
    Type of Medium: Online Resource
    ISSN: 0012-1797 , 1939-327X
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2021
    detail.hit.zdb_id: 1501252-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Gastroenterology, Elsevier BV, Vol. 164, No. 6 ( 2023-05), p. S-13-
    Type of Medium: Online Resource
    ISSN: 0016-5085
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Diabetes, American Diabetes Association, Vol. 70, No. Supplement_1 ( 2021-06-01)
    Type of Medium: Online Resource
    ISSN: 0012-1797 , 1939-327X
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2021
    detail.hit.zdb_id: 1501252-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Diabetes, American Diabetes Association, Vol. 70, No. Supplement_1 ( 2021-06-01)
    Abstract: Screening for islet autoantibodies (IAb) followed by education and monitoring of children at high risk for type 1 diabetes (T1D) substantially reduces incidence of diabetic ketoacidosis at diagnosis. We assess parental anxiety and accuracy of risk perception as part of ASK screening, education and monitoring program. The 10-y risk of clinical diabetes is 70% in children positive for multiple IAb, 50% with single high-affinity, and 2% with single low-affinity (confirmed twice). As of March 2020, ASK had screened for IAb 23,847 general population children and further monitored 280, including 136 with 50-70% high risk and 144 with 2% lower risk; 9% had a first degree relative (FDR) with T1D. At each visit, parental risk perception and anxiety were assessed using the State Anxiety Inventory (SAI), with a score & gt;40 denoting elevated anxiety. Reported here are results from the 1st visit (N=280) and for those with a 2nd visit (N=119). At the 1st visit, parental anxiety was elevated (mean SAI=46.1) with no difference by child’s risk status, family history, or by which parent responded. SAI was significantly higher in ethnic minorities than in non-Hispanic whites (p & lt;0.0001). Anxiety decreased between the 1st and 2nd education and monitoring visit from a mean of 46.1 to 43.8 (p=0.024), most notably in parents of high risk children (44.9 to 42.7 p=0.009) and FDRs (44.6 to 38.6, p=0.059). Accuracy of risk perception was low at 49% and did not improve at the 2nd visit. FDR compared to non-FDR (83% vs. 46%, p=0.004) and parents of high risk compared to low risk children had a more accurate risk perception (61% vs. 37% p & lt;0.0001). Parental anxiety after learning of a child’s positive screening result decreased rapidly in families enrolled in monitoring. However, accurate perception of T1D risk appears less malleable during the initial 3-6 months of the monitoring. Tailored intervention for parents with inaccurate risk perception may be warranted. Disclosure C. Geno rasmussen: None. J. Baxter: None. F. Dong: None. K. A. Bautista: None. F. Sepulveda: None. D. Felipe-morales: None. M. Rewers: Advisory Panel; Self; Provention Bio, Inc., Consultant; Self; RTI, Research Support; Self; Janssen Research & Development, LLC, JDRF. Funding JDRF (3-SRA-2018-564-M-N)
    Type of Medium: Online Resource
    ISSN: 0012-1797 , 1939-327X
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2021
    detail.hit.zdb_id: 1501252-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...